Global Burden of Disease Health Financing Collaborator Network. Past, present, and future of global health financing: A review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050. Lancet2019; 393: 2233–2260.
3.
XuKEvansDBKwabattaK, et al. Household catastrophic health expenditure: A multicountry analysis. Lancet2003; 362: 111–117.
4.
Laurson-DoubeJRijkeNCostelloK, et al. Health care disparities for people with MS. Lancet Neurol2020; 19: 207–208.
5.
The Lancet Neurology. Essential medicines for patients with multiple sclerosis. Lancet Neurol2019; 18(12): 1067.
6.
Laurson-DoubeJRijkeNHelmeA, et al. Ethical use of off-label therapies in multiple sclerosis. Mult Scler J2021; 27(9): 1403–1410.
7.
WaltonCKingRRechtmanL, et al. prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler2020; 26(14): 1816–1821.
8.
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol2019; 18(3): 269–285.
9.
PanditLKundapurR.Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, in South India. Mult Scler J2014; 20: 1651–1653.
10.
StankiewiczJMKolbHKarniA, et al. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics2013; 10(1): 77–88.
11.
SalzerJSvennigssonRAlpingP, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology2016; 87: 2074–2081.
12.
KisterICorboyJR.Reducing costs while enhancing quality of care in MS. Neurology2016; 87: 1617–1622.
13.
PanditLMustafaS.Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report. Neurol India2014; 62(6): 646–648.
14.
MathewTJohnSKKamathV, et al. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country. Mult Scler Relat Disord2020; 43: 102210.
